Pulmonx (LUNG) Net Income towards Common Stockholders (2019 - 2025)

Pulmonx (LUNG) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$14.0 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Net Income towards Common Stockholders rose 1.38% year-over-year to -$14.0 million in Q3 2025; TTM through Sep 2025 was -$56.7 million, a 0.71% increase from a year earlier, with the FY2024 full-year figure at -$56.4 million, up 7.31% from the prior year.
• Net Income towards Common Stockholders was -$14.0 million for Q3 2025 at Pulmonx, up from -$15.2 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$10.2 million in Q3 2021 and troughed at -$16.2 million in Q2 2023.
• A 5-year average of -$14.1 million and a median of -$14.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders tumbled 163.76% in 2021 and gained 13.22% in 2024, its largest moves.
• Over 5 years, Net Income towards Common Stockholders stood at -$13.0 million in 2021, then decreased by 9.89% to -$14.3 million in 2022, then increased by 2.77% to -$13.9 million in 2023, then rose by 5.41% to -$13.1 million in 2024, then declined by 6.24% to -$14.0 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$14.0 million (Q3 2025), -$15.2 million (Q2 2025), and -$14.4 million (Q1 2025), per Business Quant data.